Genuine Sotolaxibu is on the market, the latest price is announced!

Sotorasib is a new type of anti-cancer drug and a targeted therapy drug in the field of tumor treatment. It is unique in that it targets a specific gene mutation called KRAS G12C, which is widespread in a variety of cancers, especially non-small cell lung cancer (NSCLC).

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

KRAS G12C mutation is a common cancer driver gene mutation, which leads to abnormal activation of cell signaling pathways, thereby promoting uncontrolled proliferation and survival of cancer cells. Sotoracib is designed to specifically interfere with this specific genetic mutation, thereby blocking the growth and spread of cancer cells.

The development of this drug represents a breakthrough for theKRAS G12C mutation, which has long been considered difficult to intervene, filling a gap in the field. The launch of sotoracib provides a new treatment option for cancer patients carrying this mutation, especially in patients with non-small cell lung cancer, and brings hope to some advanced patients.

It should be emphasized that sotorasiib is not suitable for all patients with non-small cell lung cancer, but is limited to those carrying theKRAS G12C mutation. Before using this drug, genetic testing is usually required to confirm whether the patient meets the conditions for use and to ensure optimal efficacy and safety. Overall, the emergence of sotorasiib provides a new treatment prospect for cancer patients carrying the KRAS G12C mutation and highlights the continuous innovation efforts in the biomedical field.